Press Releases

Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May 5, 2016

-- Conference Call Scheduled for Thursday, May 5, 2016 at 4:30 p.m. EDT --

ROCKVILLE, Md., April, 26, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016, and to host a conference call the same day at 4:30 p.m. EDT. The dial-in information for the call is as follows:

Synthetic Biologics, Inc. www.syntheticbiologics.com

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/14380. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/14380, beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C) and (2) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). In collaboration with Intrexon Corporation, the Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - https://photos.prnewswire.com/prnh/20160105/319502LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-first-quarter-2016-operational-highlights-and-financial-results-on-may-5-2016-300257219.html

SOURCE Synthetic Biologics, Inc.